9 results about "Paliperidone" patented technology

The present application relates to the field of medical informatics, and provides a paliperidone efficacy prediction method and system based on plasma metabolomics. The method comprises the following steps: collecting basic data of a target patient; performing feature selection on metabolites through the basic data to obtain relevant metabolites corresponding to paliperidone efficacy; training a neural network based on the relevant metabolites and baseline data in the basic data to obtain a prediction model; and performing paliperidone efficacy prediction on a patient to be predicted through the prediction model to obtain a prediction result. The present application can predict the probability of patient response to paliperidone, thereby more accurately evaluating the efficacy of paliperidone before medication, and providing an auxiliary decision for individualized medication.

The present application relates to the field of medical informatics, and provide a paliperidone efficacy prediction method and system based on plasma proteomics, the method comprises the following steps: collecting the basic data of the target patient; selecting the protein features through the basic data to obtain the related proteins corresponding to the paliperidone efficacy; training the neural network based on the related proteins and the baseline data in the basic data to obtain the prediction model; predicting the paliperidone efficacy of the patient to be predicted through the prediction model to obtain the prediction result. The present application can predict the treatment response of schizophrenic patients to paliperidone, and significantly improve the objectivity of paliperidone use.

This invention belongs to the field of SNP site detection technology for guiding the use of second-generation antipsychotic drugs. Specifically, it relates to primer and probe combinations and applications for SNP site detection to guide personalized medication of second-generation antipsychotic drugs. The SNP site is rs17782313. The primer and probe combination includes an upstream primer SEQ ID NO:1 that specifically amplifies the wild-type T allele, an upstream primer SEQ ID NO:2 that specifically amplifies the mutant C allele, a universal downstream primer SEQ ID NO:3, a wild-type probe SEQ ID NO:4, and a mutant probe SEQ ID NO:5. This invention assesses the genetic risk of weight gain and metabolic disorders in patients with mental illness after taking second-generation antipsychotic drugs such as risperidone, quetiapine, amisulpride, and paliperidone through rapid and accurate genotyping. It features high specificity, high accuracy, speed, simplicity, and controllable cost, and can achieve rapid single-tube genotyping, providing key genetic evidence for the clinical development of personalized medication regimens.

1. Name of the product in this design: Pharmaceutical Packaging Box (Pariporone Extended-Release Tablets). 2. Purpose of this design: Packaging box for paliperidone sustained-release tablets. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the key design points: Design 1 3D view. 5. The design for which protection is sought includes color. 6. Design 1 is designated as the basic design.

To provide a method for treating a psychotic patient in need of treatment with a long-acting injectable paliperidone palmitate formulation.SOLUTION: A method for administering paliperidone palmitate to a patient in need thereof who has been administered a first dose of a first paliperidone palmitate extended release injectable suspension (first suspension), the method comprising: Administering a resumption loading dose of a second paliperidone palmitate extended release injectable suspension (second suspension) to the patient's deltoid muscle at a time point that is greater than 6 months and less than 3 weeks after administration of the first dose of the first suspension, and administering a maintenance dose of the first suspension to the patient's deltoid muscle or gluteus maximus muscle at a time point that is about 1 month (+ / -7 days) after administration of the resumption loading dose of the second suspension.SELECTED DRAWING: None

The invention discloses a paliperidone coated tablet. The paliperidone coated tablet comprises a tablet core layer and a shell layer, the tablet core layer comprises the following components in parts by weight: 5-10 parts of paliperidone, 1-2 parts of a plasticizer, 0.1-0.5 part of a flow aid, 10-30 parts of a carrier, 22-28 parts of a retardant A, 40-70 parts of a sustained-release material A and 0.1-0.5 part of a lubricant A, wherein the sum of the parts of the raw materials is 100; the shell layer comprises the following components in parts by weight: 0.5-0.8 part of paliperidone, 250-260 parts of a sustained-release material B, 60-70 parts of a retardant B and 1-2 parts of a lubricant B, and the sum of the parts by weight of the raw materials is 320. The composition is simple in components, convenient to use, simple in preparation process and controllable in cost.

The invention relates to a method for detecting related substances in paliperidone, in particular to a method for simultaneously detecting eight known impurities in paliperidone by adopting a high performance liquid chromatography, the method can realize effective separation and determination of the eight known impurities in paliperidone, the separation degree is high, the system durability is strong, and the method is suitable for industrial production. The method is simple in operation, high in detection sensitivity and accuracy, capable of ensuring controllable quality of paliperidone raw material medicines and preparations, simple to operate and suitable for industrial application.

To provide a method for treating a psychotic patient in need of treatment with a long-acting injectable paliperidone palmitate formulation.SOLUTION: A method for administering paliperidone palmitate to a patient in need thereof who has been administered a first dose of paliperidone palmitate sustained release injectable suspension, comprising administering a second dose of the paliperidone palmitate sustained release injectable suspension to the deltoid or gluteal muscle of the patient up to two weeks before or three weeks after a time point that is six months after administration of the first dose, wherein there are no intervening doses of paliperidone palmitate between the first dose and the second dose.SELECTED DRAWING: None

The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations.